retatrutide and perimenopause for Women Over 40: 25% Weight Loss Results Menopausal Transition (Perimenopause) | ReproductiveFacts.org

For now, we will have to take it by injection once a week

Tirzepatide is a dual agonist (GLP-1 and GIP)

Its simultaneous activation of three receptor pathways GLP-1R for appetite suppression and insulin secretion, GIPR for augmented insulin response and central appetite modulation, and GCGR for energy expenditure and hepatic fat mobilisation produces metabolic effects that exceed what single or dual agonism can achieve [4][8][9]

As of 2025, retatrutide has not received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) or the European Medicines Agency (EMA) for routine clinical use in the UK

The glucagon-like peptide 1 receptor agonist exendin-4 induces tenogenesis in human mesenchymal stem cells

Once a prescription has been approved and processing has begun, the order cannot be canceled for refund